News | October 31, 2023
Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Six engaging sessions focusing on Prevention of Kidney Diseases, Brain Stem Death Declaration, Deceased Donor Management, Prevention of Liver Diseases, Legal Aspects of Organ and Tissue Donation, Eye Donation and Corneal Transplant held as part of the Webinar
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Women of all ages will get round-the-clock access to comprehensive treatment
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Funds raised will be used to develop technology and foster healthcare partnerships
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Subscribe To Our Newsletter & Stay Updated
